The Michigan Genetic Hereditary Testing (MiGHT) Study's Innovative Approaches to Promote Uptake of Clinical Genetic Testing Among Cancer Patients: a Study Protocol for a 3-arm Randomized Controlled Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2023 Feb 11

PMID 36765432

Authors

Lynette Hammond Gerido

Jennifer J Griggs

Ken Resnicow

Kelley M Kidwell

Emerson Delacroix

Sarah Austin

Erika N Hanson

Elizabeth Bacon

Erika Koeppe

Stefanie Goodall

Matthew Demerath

Elizabeth A Rizzo

Shayna Weiner

Sarah T Hawley

Wendy R Uhlmann

J Scott Roberts

Elena M Stoffel

Affiliations

Soon will be listed here.

Abstract

Background: Although most cancers are sporadic, germline genetic variants are implicated in 5-10% of cancer cases. Clinical genetic testing identifies pathogenic germline genetic variants for hereditary cancers. The Michigan Genetic Hereditary Testing (MiGHT) study is a three-arm randomized clinical trial that aims to test the efficacy of two patient-level behavioral interventions on uptake of cancer genetic testing.

Methods: The two interventions being tested are (1) a virtual genetics navigator and (2) motivational interviewing by genetic health coaches. Eligible participants are adults with a diagnosis of breast, prostate, endometrial, ovarian, colorectal, or pancreatic cancer who meet the National Comprehensive Cancer Network (NCCN) criteria for genetic testing. Participants are recruited through community oncology practices affiliated with the Michigan Oncology Quality Consortium (MOQC) and have used the Family Health History Tool (FHHT) to determine testing eligibility. The recruitment goal is 759 participants, who will be randomized to usual care or to either the virtual genetics navigator or the motivational interviewing intervention arms. The primary outcome will be the proportion of individuals who complete germline genetic testing within 6 months.

Discussion: This study addresses patient-level factors which are associated with the uptake of genetic testing. The study will test two different intervention approaches, both of which can help address the shortage of genetic counselors and improve access to care.

Trial Registration: This study has been approved by the Institutional Review Board of the University of Michigan Medical School (HUM00192898) and registered in ClinicalTrials.gov (NCT05162846).

Citing Articles

Internet-Based Abnormal Chromosomal Diagnosis During Pregnancy Using a Noninvasive Innovative Approach to Detecting Chromosomal Abnormalities in the Fetus: Scoping Review.

Oyovwi M, Ohwin E, Rotu R, Olowe T JMIR Bioinform Biotechnol. 2024; 5:e58439.

PMID: 39412876 PMC: 11525087. DOI: 10.2196/58439.

Impact of barriers and motivators on intention and confidence to undergo hereditary cancer genetic testing.

Austin S, Hanson E, Delacroix E, Bacon E, Rice J, Gerido L J Genet Couns. 2024; 34(1):e1926.

PMID: 38803214 PMC: 11599461. DOI: 10.1002/jgc4.1926.

Expanding access to genetic testing for pancreatic cancer.

Rodriguez N, Syngal S Fam Cancer. 2024; 23(3):247-254.

PMID: 38733419 PMC: 11532997. DOI: 10.1007/s10689-024-00389-w.

References

Hoskovec J, Bennett R, Carey M, DaVanzo J, Dougherty M, Hahn S . Projecting the Supply and Demand for Certified Genetic Counselors: a Workforce Study. J Genet Couns. 2017; 27(1):16-20. DOI: 10.1007/s10897-017-0158-8. View

Richardson M, Min H, Hong Q, Compton K, Mung S, Lohn Z . Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System. Cancers (Basel). 2020; 12(2). PMC: 7072228. DOI: 10.3390/cancers12020338. View

Stenehjem D, Au T, Sainski A, Bauer H, Brown K, Lancaster J . Impact of a genetic counseling requirement prior to genetic testing. BMC Health Serv Res. 2018; 18(1):165. PMC: 5842549. DOI: 10.1186/s12913-018-2957-5. View

Thompson H, Valdimarsdottir H, Winkel G, Jandorf L, Redd W . The Group-Based Medical Mistrust Scale: psychometric properties and association with breast cancer screening. Prev Med. 2004; 38(2):209-18. DOI: 10.1016/j.ypmed.2003.09.041. View

Abul-Husn N, Soper E, Odgis J, Cullina S, Bobo D, Moscati A . Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med. 2020; 12(1):2. PMC: 6938627. DOI: 10.1186/s13073-019-0691-1. View

Giri V, Hegarty S, Hyatt C, OLeary E, Garcia J, Knudsen K . Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Prostate. 2018; 79(4):333-339. DOI: 10.1002/pros.23739. View

McMaster F, Resnicow K . Validation of the one pass measure for motivational interviewing competence. Patient Educ Couns. 2015; 98(4):499-505. DOI: 10.1016/j.pec.2014.12.014. View

Baldry E, Redlinger-Grosse K, MacFarlane I, Walters S, Ash E, Steinberger J . Outcomes from a pilot genetic counseling intervention using motivational interviewing and the extended parallel process model to increase cascade cholesterol screening. J Genet Couns. 2021; 31(1):164-175. DOI: 10.1002/jgc4.1466. View

Stoll K, Kubendran S, Cohen S . The past, present and future of service delivery in genetic counseling: Keeping up in the era of precision medicine. Am J Med Genet C Semin Med Genet. 2018; 178(1):24-37. DOI: 10.1002/ajmg.c.31602. View

10.

Khoury M, Coates R, Fennell M, Glasgow R, Scheuner M, Schully S . Multilevel research and the challenges of implementing genomic medicine. J Natl Cancer Inst Monogr. 2012; 2012(44):112-20. PMC: 3482965. DOI: 10.1093/jncimonographs/lgs003. View

11.

Fecteau H, Vogel K, Hanson K, Morrill-Cornelius S . The evolution of cancer risk assessment in the era of next generation sequencing. J Genet Couns. 2014; 23(4):633-9. DOI: 10.1007/s10897-014-9714-7. View

12.

Thompson H, Valdimarsdottir H, Guevarra J, Bovbjerg D, Amarel D, Godfrey D . Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1579-85. View

13.

Manrriquez E, Chapman J, Mak J, Blanco A, Chen L . Disparities in genetics assessment for women with ovarian cancer: Can we do better?. Gynecol Oncol. 2018; 149(1):84-88. DOI: 10.1016/j.ygyno.2017.10.034. View

14.

Katapodi M, Northouse L, Schafenacker A, Duquette D, Duffy S, Ronis D . Using a state cancer registry to recruit young breast cancer survivors and high-risk relatives: protocol of a randomized trial testing the efficacy of a targeted versus a tailored intervention to increase breast cancer screening. BMC Cancer. 2013; 13:97. PMC: 3599993. DOI: 10.1186/1471-2407-13-97. View

15.

Miller W, Rose G . Toward a theory of motivational interviewing. Am Psychol. 2009; 64(6):527-37. PMC: 2759607. DOI: 10.1037/a0016830. View

16.

Pollard S, Kalloger S, Weymann D, Sun S, Nuk J, Schrader K . Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication. Health Expect. 2020; 23(4):884-892. PMC: 7495068. DOI: 10.1111/hex.13062. View

17.

Robson M, Offit K . Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med. 2007; 357(2):154-62. DOI: 10.1056/NEJMcp071286. View

18.

Larkin C, Wijesundara J, Nguyen H, Ha D, Vuong A, Nguyen C . mHealth Messaging to Motivate Quitline Use and Quitting: Protocol for a Community-Based Randomized Controlled Trial in Rural Vietnam. JMIR Res Protoc. 2021; 10(10):e30947. PMC: 8532014. DOI: 10.2196/30947. View

19.

Lundahl B, Moleni T, Burke B, Butters R, Tollefson D, Butler C . Motivational interviewing in medical care settings: a systematic review and meta-analysis of randomized controlled trials. Patient Educ Couns. 2013; 93(2):157-68. DOI: 10.1016/j.pec.2013.07.012. View

20.

McClain M, Palomaki G, Nathanson K, Haddow J . Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med. 2005; 7(1):28-33. DOI: 10.1097/01.gim.0000151155.36470.ff. View